The
report provides comprehensive information on the therapeutics under development
for Retinopathy Of Prematurity, complete with analysis by stage of development,
drug target, mechanism of action (MoA), route of administration (RoA) and
molecule type. The report also covers the descriptive pharmacological action of
the therapeutics, its complete research and development history and latest news
and press releases. Additionally, the report provides an overview of key
players involved in therapeutic development for Retinopathy Of Prematurity and
features dormant and discontinued projects.
Global
Markets Direct’s report features investigational drugs from across globe
covering over 20 therapy areas and nearly 3,000 indications. The report is
built using data and information sourced from Global Markets Direct’s
proprietary databases, company/university websites, clinical trial registries,
conferences, SEC filings, investor presentations and featured press releases
from company/university sites and industry-specific third party sources. Drug
profiles featured in the report undergoes periodic review following a stringent
set of processes to ensure that all the profiles are updated with the latest
set of information. Additionally, various dynamic tracking processes ensure
that the most recent developments are captured on a real time basis.
The
report helps in identifying and tracking emerging players in the market and
their portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.
Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/146006
.
For more information contact sales@orbisresearch.com
Scope:
- The report provides a snapshot of the global therapeutic landscape of Retinopathy Of Prematurity
- The report reviews pipeline therapeutics for Retinopathy Of Prematurity by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Retinopathy Of Prematurity therapeutics and enlists all their major and minor projects
- The report assesses Retinopathy Of Prematurity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Retinopathy Of Prematurity
- The report provides a snapshot of the global therapeutic landscape of Retinopathy Of Prematurity
- The report reviews pipeline therapeutics for Retinopathy Of Prematurity by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Retinopathy Of Prematurity therapeutics and enlists all their major and minor projects
- The report assesses Retinopathy Of Prematurity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Retinopathy Of Prematurity
Browse Complete Report @ http://www.orbisresearch.com/reports/index/retinopathy-of-prematurity-pipeline-review-h2-2016 .
Some Points Of List of Figures
Number of Products under Development for Retinopathy Of Prematurity, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Early Stage Products, H2 2016 10
Assessment by Monotherapy Products, H2 2016 14
Number of Products by Targets, H2 2016 15
Number of Products by Stage and Targets, H2 2016 15
Number of Products by Mechanism of Actions, H2 2016 17
Number of Products by Stage and Mechanism of Actions, H2 2016 17
Number of Products by Routes of Administration, H2 2016 19
Number of Products by Stage and Routes of Administration, H2 2016 19
Number of Products by Molecule Types, H2 2016 21
Number of Products by Stage and Molecule Types, H2 2016 21
Number of Products under Development for Retinopathy Of Prematurity, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Early Stage Products, H2 2016 10
Assessment by Monotherapy Products, H2 2016 14
Number of Products by Targets, H2 2016 15
Number of Products by Stage and Targets, H2 2016 15
Number of Products by Mechanism of Actions, H2 2016 17
Number of Products by Stage and Mechanism of Actions, H2 2016 17
Number of Products by Routes of Administration, H2 2016 19
Number of Products by Stage and Routes of Administration, H2 2016 19
Number of Products by Molecule Types, H2 2016 21
Number of Products by Stage and Molecule Types, H2 2016 21
For
any enquires before buying, connect with us @ enquiry@orbisresearch.com
About Us:
Orbis Research (orbisresearch.com) is a
single point aid for all your market research requirements. We have vast
database of reports from the leading publishers and authors across the globe.
We specialize in delivering customized reports as per the requirements of our
clients. We have complete information about our publishers and hence are sure
about the accuracy of the industries and verticals of their specialization.
This helps our clients to map their needs and we produce the perfect required
market research study for our clients.
Contact
Information:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1
(214) 884-6817; +9164101019
Follow Us on
LinkedIn: https://www.linkedin.com/company/orbis-research
Follow us on Twitter: https://twitter.com/orbisresearch
No comments:
Post a Comment